# Safety and Efficacy Study of Catumaxomab to Treat Ovarian Cancer After a Complete Response to Chemotherapy

Source: https://onco.cc/trials/nct00377429/  
OnCo record `nct00377429` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Catumaxomab in Ovarian cancer, run by Neovii Biotech, completed.

## Summary

Safety and Efficacy Study of Catumaxomab to Treat Ovarian Cancer After a Complete Response to Chemotherapy is a phase 2 interventional study registered as NCT00377429 by Neovii Biotech, with 47 participants recorded, started 2006-09 and reaching its primary completion in 2008-02. Interventions recorded: catumaxomab. Conditions recorded: Ovarian Cancer.

Linked to the drug Catumaxomab because the registry names it among its interventions and Ovarian cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT00377429
- Phase: 2
- Setting: An Open-Label, Single-Arm, Phase II Safety and Tolerability Study of Catumaxomab (Anti-EpCAM x Anti-CD3) in Women With Advanced Epithelial Ovarian Cancer After a Complete Response to Chemotherapy
- Sponsor: Neovii Biotech
- Enrolled: 47

## Sources

- ClinicalTrials.gov NCT00377429: https://clinicaltrials.gov/study/NCT00377429

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- drugs: [Catumaxomab](https://onco.cc/drugs/catumaxomab/)
- companies: [Neovii](https://onco.cc/companies/neovii/)

---
JSON: https://onco.cc/api/v1/entities/nct00377429.json